

## Refine Search

### Search Results -

Terms	Documents
L2 and antibod\$3	116

**Database:**

US Pre-Grant Publication Full-Text Database  
US Patents Full-Text Database  
US OCR Full-Text Database  
EPO Abstracts Database  
JPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Search:**

L3

Refine Search

Recall Text

Clear

Interrupt

### Search History

**DATE:** Tuesday, October 11, 2005   [Printable Copy](#)   [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>			
<u>L3</u>	L2 and antibod\$3	116	<u>L3</u>
<u>L2</u>	L1 and diagnos\$3	118	<u>L2</u>
<u>L1</u>	ubiquitin adj fusion adj protein	250	<u>L1</u>

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 15:16:42 ON 11 OCT 2005)

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, SCISEARCH, USPATFULL,  
PCTFULL'

ENTERED AT 15:17:19 ON 11 OCT 2005

L1 2272210 S UBIQUITIN(W)FUSION(W)PROTEIN? OR POLYPEPTIDE? OR  
PEPTIDE?

L2 6 S DIAGNOS? S ANTIBOD?

L3 439650 S ANTIBOD? AND L1

L4 129318 S L3 AND DIAGNOS?

L5 229019 S L1(S)ANTIBOD?

L6 6 S L1 AND L2



L7 516 S UBIQUITIN(W)FUSION(W)PROTEIN

L8 151145 S ANTIBOD?(S)DIAGNOS?

L9 129 S L7 AND L8

L10 129 DUP REM L9 (0 DUPLICATES REMOVED)

L11 28 S L9 AND 1960-1998/PY



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

Display Abstract Show 20 Sort by Send to

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Mol Immunol. 1997 Nov-Dec;34(16-17):1113-20.

Related Articles, Links

**Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope.****Dalum I, Jensen MR, Gregorius K, Thomasen CM, Elsner HI, Mouritsen S.**

M&amp;E Biotech A/S, Horsholm, Denmark.

Self proteins are handled in the same way as foreign proteins by antigen presenting cells, but because of T-cell tolerance the presentation of self peptides does not normally lead to T cell activation. By providing physically linked T-cell help it is possible to overcome the B cell non-responsiveness toward self antigens. We have shown previously that a very potent antibody response, cross-reactive with a self protein, can be rapidly induced by immunizing with a recombinant immunogen consisting of the self protein with a foreign immunodominant T helper epitope inserted into its sequence (Dalum, I., Jensen, M. R., Hindersson, P., Elsner, H. I. and Mouritsen, S. (1996) *J. Immunol.* 157, 4796). In this study we compare this approach for inducing autoantibodies against a self protein with the traditional method of conjugating the self antigen to a foreign carrier protein. The highly conserved self protein ubiquitin with an inserted epitope from ovalbumin (UbiOVA) is used as a model protein and compared to two traditionally conjugated immunogens consisting of ubiquitin chemically conjugated to a peptidic T helper epitope or to ovalbumin. The traditionally conjugated immunogens induce much slower and low titered ubiquitin specific antibody responses than the recombinant construct which also is capable of inducing antibodies directed against a much broader range of potential ubiquitin B cell determinants than the chemically conjugated immunogens. All three constructs are processed by antigen presenting cells and ovalbumin derived T cell epitopes are presented to T helper cells. From these observations it seems likely that the presence of non-shielded autologous B cell determinants on the immunogen is critical for the ability to induce a strong autoantibody response with a diverse fine specificity. Furthermore, the ubiquitin specific antibodies induced by UbiOVA contain higher levels of IgG2a/b relative to IgG1 compared to the conjugates. We therefore

speculate that the insertion of a T cell epitope directly into the self antigen could possibly induce an immune response with a different Th1/Th2 balance than a response induced with traditional conjugates.

PMID: 9566759 [PubMed - indexed for MEDLINE]

---

Display  Show  Sort by  Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 6 2005 04:38:59